Opinion|Videos|May 21, 2025
Place of Continuous Subcutaneous Infusion Systems in Parkinson Disease Management
Panelists discuss how continuous subcutaneous infusion systems should be strategically positioned within Parkinson disease management, typically as options for patients with advanced disease experiencing motor fluctuations despite optimized oral therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Placement of Infusion Therapies in Parkinson Disease Management
- Consider after oral medication optimization fails to provide adequate control
- Position before deep brain stimulation (DBS) in treatment algorithm
- Appropriate for patients with medication-responsive symptoms but problematic motor fluctuations
- Viable option when cognitive/psychiatric issues contraindicate DBS
- Can be used as a transitional therapy before considering more invasive options
- Particularly valuable for patients with unpredictable off periods
- May be considered earlier in disease course than traditionally recommended for advanced therapies
- Best implemented with a multidisciplinary team approach (neurology, nursing, pharmacy)
- Should be part of a comprehensive care plan addressing motor and nonmotor symptoms
Advertisement
Related to this article
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5